You are viewing the site in preview mode
Skip to main content
| |
Erenumab cohort (N = 3171)
|
OnabotA subgroup (N = 720)
|
|---|
|
Age at index date, mean (SD)
|
50.7 (13.6)
|
51.1 (13.2)
|
|
Female, n (%)
|
2689 (84.8)
|
628 (87.2)
|
|
CM in 12 month pre-index period, n (%)
|
1982 (62.5)
|
685 (95.1)
|
|
Index physician specialty, n (%)
|
|
Neurologist/headache specialist
|
2159 (68.1)
|
513 (71.3)
|
|
General practitioner
|
439 (13.8)
|
78 (10.8)
|
|
Nurse/physician assistant
|
293 (9.2)
|
68 (9.4)
|
|
Unknown/missing
|
154 (4.9)
|
34 (4.7)
|
|
Other specialist
|
59 (1.9)
|
11 (1.5)
|
|
Other HCP
|
52 (1.6)
|
12 (1.7)
|
|
Psychiatrist/psychologist
|
15 (0.5)
|
4 (0.6)
|
|
Region, n (%)
|
|
South
|
1536 (48.4)
|
301 (41.8)
|
|
West
|
684 (21.6)
|
205 (28.5)
|
|
Midwest
|
667 (21.0)
|
146 (20.3)
|
|
Northeast
|
284 (9.0)
|
68 (9.4)
|
|
Insurance type, n (%)
|
|
Point of service (POS)
|
1569 (49.5)
|
359 (49.9)
|
|
Other
|
741 (23.4)
|
179 (24.9)
|
|
Health maintenance organization (HMO)
|
518 (16.3)
|
114 (15.8)
|
|
Exclusive provider organization (EPO)
|
214 (6.7)
|
38 (5.3)
|
|
Preferred provider organization (PPO)
|
129 (4.1)
|
30 (4.2)
|
|
Selected comorbidities in 12 month pre-index period (> 10%), n (%)
|
|
Anxiety
|
1304 (41.1)
|
343 (47.6)
|
|
CV disease
|
1298 (40.9)
|
304 (42.2)
|
|
Depression
|
1295 (40.8)
|
337 (46.8)
|
|
Insomnia
|
731 (23.1)
|
176 (24.4)
|
|
Obesity
|
601 (19.0)
|
141 (19.6)
|
|
Fibromyalgia
|
434 (13.7)
|
109 (15.1)
|
|
Constipation
|
421 (13.3)
|
113 (15.7)
|
- CM chronic migraine, CV cardiovascular, hcp health care practitioner, n number, onabotA onabotulinumtoxinA, SD standard deviation, w/o without
